Artificial Lung Market Report 2026

Artificial Lung Market Overview

• Artificial Lung market size has reached to $2.58 billion in 2025 • Expected to grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 10.4% • Growth Driver: The Rising Prevalence Of Respiratory Diseases Fuels Artificial Lung Market • Market Trend: Advancing Portable Extracorporeal Support With Next-Generation Pneumatic ECMO Systems • North America was the largest region in 2025.

What Is Covered Under Artificial Lung Market?

An artificial lung refers to a medical device designed to take over the function of natural lungs, providing oxygen to the blood and removing carbon dioxide. It is typically used in patients with severe respiratory failure or during surgeries that require the heart and lungs to be temporarily non-functional. This technology aims to support or replace lung function, allowing patients to survive and recover from critical conditions. The main product types of artificial lungs are single roller pump heart-lung machines, double roller pump heart-lung machines, bubble artificial lungs, and membrane artificial lungs. A single roller pump heart-lung machine refers to a medical device that uses a single roller pump to circulate blood through an artificial lung and back into the patient during cardiopulmonary bypass surgery. These machines find applications in cardiac surgery, lung transplant operations, acute respiratory failure treatments, and others and are utilized by various end users such as hospitals, emergency centers, and others.

What Is The Artificial Lung Market Growth Forecast?

The artificial lung market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing demand for critical care life-support devices, growing focus on portable and compact artificial lung systems, rising investment in advanced oxygenation membrane materials, expansion of applications in emergency and trauma care, increasing adoption of minimally invasive extracorporeal support solutions. Major trends in the forecast period include increasing demand for artificial lung systems in severe respiratory failure and critical care management, rising adoption of extracorporeal support devices in complex cardiac and lung transplant surgeries, growing preference for minimally invasive and temporary lung support alternatives to transplantation, increasing development of portable and transport-compatible artificial lung units for emergency care settings, expanding use of membrane-based artificial lung technologies for efficient gas exchange and long-term support.

Global Artificial Lung Market Segmentation

1) By Product Type: Single Roller Pump Heart Lung Machines, Double Roller Pump Heart Lungs Machines, Bubble Artificial Lung, Membrane Artificial Lung 2) By Application: Cardiac Surgery, Lung Transplant Operation, Acute Respiratory Failure Treatment, Other Applications 3) By End-Users: Hospital, Emergency Center, Other End-users Subsegments: 1) By Single Roller Pump Heart Lung Machines: Portable Single Roller Pump Heart Lung Machines, Stationary Single Roller Pump Heart Lung Machines 2) By Double Roller Pump Heart Lung Machines: Portable Double Roller Pump Heart Lung Machines, Stationary Double Roller Pump Heart Lung Machines 3) By Bubble Artificial Lung: Disposable Bubble Artificial Lung, Reusable Bubble Artificial Lung 4) By Membrane Artificial Lung: Oxygenator Membrane Artificial Lung, Carbon Dioxide Removal Membrane Artificial Lung

What Is The Driver Of The Artificial Lung Market?

The increasing prevalence of respiratory diseases is expected to propel the growth of the artificial lung market going forward. The prevalence of respiratory diseases is increasing due to a combination of factors, including rising air pollution, climate change, and lifestyle changes, leading to a significant burden on public health. Artificial lungs are used in respiratory diseases to provide oxygenation and remove carbon dioxide from the blood, supporting or replacing impaired lung function. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based health and welfare agency, approximately 8.5 million people in Australia, or 34% of the population, were estimated to have chronic respiratory conditions. This includes an estimated 2.8 million people, or 11% of the population, living with asthma, and 638,000 people, or 2.5% of the population, living with chronic obstructive pulmonary disease (COPD). Therefore, the increasing prevalence of respiratory diseases is driving the growth of the artificial lung industry.

Key Players In The Global Artificial Lung Market

Major companies operating in the artificial lung market are Getinge AB, Medtronic plc, LivaNova PLC, Terumo Corporation, Fresenius Medical Care AG & Co KGaA, ALung Technologies Inc, Xenios AG, Eurosets S.r.l, Nipro Corporation, Braile Biomédica, Hemovent GmbH, MC3 Cardiopulmonary Inc, Abbott Laboratories, Spectrum Medical Ltd, B Braun Melsungen AG, SB‑Kawasumi Laboratories Inc, Senko Medical Instrument Mfg Co Ltd, CARMAT, Technowood International Pte Ltd, Elite Lifecare, Cytosorbents Corporation

Global Artificial Lung Market Trends and Insights

Major companies operating in the artificial lung market are focusing on developing innovative solutions, such as truly portable pneumatic ECMO systems, to expand extracorporeal life support beyond the ICU and enable rapid transport and field deployment. A pneumatic portable ECMO system uses oxygen-supply-driven pneumatic pumps and integrated gas management to provide extracorporeal oxygenation and circulatory support without reliance on external electric power or heavy motorised components. For instance, in May 2024, Hemovent GmbH, a Germany-based medical device company, announced that MOBYBOX, the world’s first integrated portable pneumatic ECMO system, completed its initial commercial applications in Europe; MOBYBOX weighs about 2.5 kg, is driven solely by the oxygen supply so it operates without a battery or motor, features Bionique Flow Technology for gentler blood handling and improved gas exchange, and has obtained Medical Device Regulation certification for initial markets.

What Are Latest Mergers And Acquisitions In The Artificial Lung Market?

In August 2024, Getinge AB, a Sweden-based medical technology company, completed the acquisition of Paragonix Technologies for about US$477 million. The acquisition aims to expand Getinge’s organ preservation and transplant logistics offering by adding Paragonix’s advanced organ transport and storage systems, improving transplant outcomes and strengthening Getinge’s position in cardiac and thoracic transplant workflows. Paragonix Technologies is a US-based company specializing in organ preservation and transport solutions for cardiac and thoracic transplantation.

Regional Outlook

North America was the largest region in the artificial lung market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Artificial Lung Market?

The artificial lung market consists of sales of extracorporeal membrane oxygenation (ECMO), intravenous membrane oxygenators (IVOX), bioartificial lungs, and microfluidic artificial lungs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.